UBX7 Antibody

What is UBXN7 and what are its key functional domains?

UBXN7 is a member of the ubiquitin regulatory X (UBX) domain-containing protein family that functions as a cofactor for p97 (also known as VCP), an AAA+ ATPase involved in various cellular processes including protein degradation. UBXN7 contains several functional domains:

• UBX domain: Mediates interaction with p97

• UBA (ubiquitin-associated) domain: Binds to ubiquitinated proteins

• UAS domain: Critical for UBXN7's effects on NF-κB signaling and autophagy

Research has shown that the UBX domain is essential for UBXN7's interaction with both p97 and ubiquitinated substrates. An UBXN7 mutant lacking the UBX domain loses the ability to interact with p97 and ubiquitinated substrates, although it still retains some capacity to bind cullin proteins like CUL1 and CUL2 .

What are the main applications for UBXN7 antibodies in research?

UBXN7 antibodies are valuable tools in multiple research applications:

When selecting antibodies for these applications, researchers should consider specificity, sensitivity, and validated applications provided by manufacturers .

What controls should I include when working with UBXN7 antibodies?

Proper controls are essential for interpreting results with UBXN7 antibodies:

• Positive control: Cell lysates known to express UBXN7 (e.g., HepG2, Huh7, or HEK293T cells)

• Negative control: Lysates from cells with UBXN7 knockdown via siRNA (as shown in HIF1α validation studies)

• Isotype control: Matching antibody isotype (e.g., IgG1 for monoclonal antibodies)

• Loading control: Detection of housekeeping proteins like GAPDH or β-actin

It's particularly important to validate antibody specificity using siRNA-mediated knockdown, as demonstrated in studies examining UBXN7-HIF1α interactions, where researchers confirmed antibody specificity by comparing signals in cells treated with or without UBXN7 siRNA .

How does UBXN7 interact with the ubiquitin-proteasome system?

UBXN7 functions as a bridge between the p97 ATPase complex and ubiquitinated substrates targeted for proteasomal degradation. Its interactions with the ubiquitin-proteasome system are multifaceted:

• UBXN7 binds ubiquitinated proteins through its UBA domain

• It interacts with multiple E3 ubiquitin ligases, particularly cullin-RING ligases (CRLs)

• It shows remarkable specificity for CUL2-containing complexes

• UBXN7 co-immunoprecipitates with RBX1, elongin B, elongin C, and VHL (components of CRL2 complexes)

For experimental approaches to study these interactions:

• Use MudPIT (Multidimensional Protein Identification Technology) analysis of UBXN7 immunoprecipitates to identify interacting partners

• Perform in vivo ubiquitination assays with HA-tagged ubiquitin, Flag-tagged UBXN7, and potential substrates

• Use mutational analysis of UBXN7 domains to map interaction sites

Research has shown that UBXN7 promotes K48-linked ubiquitination of IKK-β, leading to its degradation and subsequent reduction in NF-κB signaling .

What is the role of UBXN7 in HBV replication and how can it be studied experimentally?

UBXN7 functions as a novel inhibitor of hepatitis B virus (HBV) replication through several mechanisms:

• UBXN7 inhibits NF-κB signaling by promoting IKK-β degradation

• This reduction in NF-κB activity leads to decreased autophagy

• Decreased autophagy results in reduced HBV replication

• HBV counteracts this by producing HBx protein, which targets UBXN7 for degradation

Experimental approaches to study UBXN7's role in HBV replication:

Research has demonstrated that overexpression of UBXN7 reduces HBV RNA levels in a dose-dependent manner in multiple cell lines including Huh7, HepG2, and HepG2.2.15, while knocking down UBXN7 increases viral replication .

How can I study UBXN7's interaction with HIF1α and its role in hypoxia response?

UBXN7 has been shown to interact with HIF1α, a key transcription factor in hypoxia response. This interaction is enhanced when proteasome activity is inhibited with MG132, suggesting UBXN7 plays a role in HIF1α degradation. To study this interaction:

• Immunoprecipitate UBXN7 and probe for HIF1α

  • Use MG132 treatment to accumulate ubiquitinated HIF1α

  • Include proper controls to identify cross-reacting bands

• Examine the role of p97 in this interaction

  • Use p97 inhibitors or dominant-negative p97 mutants

  • Create UBXN7 mutants lacking specific domains to map interaction sites

• Analyze how hypoxia affects UBXN7-HIF1α binding

  • Compare normoxic vs. hypoxic conditions

  • Use CoCl2 as a chemical hypoxia mimetic

Research has shown that among UBA-UBX proteins, UBXN7 is particularly efficient at co-immunoprecipitating HIF1α, which appears as a ubiquitinated ladder when detected with anti-HIF1α antibodies. This interaction is only detectable after MG132 treatment, which causes accumulation of ubiquitinated HIF1α .

What methodologies are optimal for studying UBXN7's interactions with cullin-RING ligases (CRLs)?

UBXN7 shows remarkable ability to interact with cullin-RING ligases, particularly those containing CUL2. To study these interactions:

• Co-immunoprecipitation approaches:

  • Use Flag-tagged UBXN7 to pull down CRL components

  • Perform reverse IP with antibodies against CUL1, CUL2, or other CRL components

  • Include controls with UBXN7 mutants lacking specific domains

• Domain mapping studies:

  • Create truncation mutants of UBXN7 lacking UBX, UBA, or other domains

  • Assess which domains are required for CRL binding

  • Use site-directed mutagenesis to identify critical residues

• Functional assays:

  • Assess the effect of UBXN7 on CRL-mediated substrate ubiquitination

  • Study how UBXN7 affects the stability of known CRL substrates

  • Examine whether p97 recruitment by UBXN7 influences CRL activity

Research has demonstrated that UBXD7 (UBXN7) showed remarkable ability to co-immunoprecipitate CUL2 as well as RBX1, elongin B, elongin C, and VHL. Among UBA-UBX proteins, UBXD7 showed the most extensive interaction with CRL subunits .

How can I analyze UBXN7's effects on NF-κB signaling pathways?

UBXN7 has been identified as an inhibitor of NF-κB signaling. To study this function:

• NF-κB activity assays:

  • Use dual-luciferase reporter assays with NF-κB responsive promoters

  • Compare cells with UBXN7 overexpression, knockdown, or domain mutants

  • Include TNF-α stimulation to activate the pathway

• Interaction studies:

  • Test UBXN7 binding to NF-κB pathway components (IKK-β, IκBα, p65, etc.)

  • Map domains involved in these interactions

  • Assess how these interactions change upon pathway activation

• Ubiquitination analysis:

  • Examine how UBXN7 affects K48 vs. K63 ubiquitination of IKK-β

  • Use ubiquitin mutants (K48-only or K63-only) to confirm specificity

  • Perform in vivo ubiquitination assays with proteasome inhibitors

Experimental evidence shows that UBXN7 interacts with IKK-β (but not with IκBα, p65, TAK1, or IKK-α) and promotes its K48-linked ubiquitination and subsequent degradation. UBXN7 overexpression decreases HBV-induced NF-κB responsive promoter activity, while the UAS domain of UBXN7 is essential for this inhibitory effect .

How can I improve detection of endogenous UBXN7 in Western blots?

Detecting endogenous UBXN7 can be challenging due to its relatively low expression levels in some cell types. To improve detection:

• Sample preparation optimization:

  • Use RIPA buffer with fresh protease inhibitors

  • Include deubiquitinase inhibitors like N-ethylmaleimide (5-10 mM)

  • Perform sample concentration if needed (TCA precipitation)

• Antibody selection and optimization:

  • Test multiple antibodies recognizing different epitopes

  • Optimize antibody dilution (typically 1:500-1:2000)

  • Increase incubation time (overnight at 4°C)

• Detection system considerations:

  • Use high-sensitivity ECL substrates

  • Consider fluorescent secondary antibodies for quantitative analysis

  • Increase exposure time while monitoring background

When studying UBXN7 in the context of viral infections like HBV, expression levels may change, with HBV infection reducing UBXN7 levels by approximately 50% in HepG2.2.15 cells compared to HepG2 cells .

What are common pitfalls when studying UBXN7-mediated ubiquitination?

When analyzing UBXN7's roles in ubiquitination pathways, researchers should be aware of several technical challenges:

• Distinguishing ubiquitination types:

  • Use specific antibodies for K48 vs. K63 linkages

  • Employ ubiquitin mutants (K48R, K63R, K48-only, K63-only)

  • Include appropriate controls with proteasome inhibitors

• Preventing deubiquitination during sample preparation:

  • Work quickly and maintain samples at 4°C

  • Include deubiquitination inhibitors in all buffers

  • Denature samples immediately in SDS buffer containing reducing agents

• Confirming specificity of observed effects:

  • Use domain mutants to map functional regions

  • Perform rescue experiments with siRNA-resistant constructs

  • Include negative controls targeting unrelated UBX proteins

Research has shown that when studying UBXN7's effects on IKK-β ubiquitination, it's crucial to include both wild-type ubiquitin and K48/K63-specific mutants in the analysis, as UBXN7 specifically promotes K48-linked (but not K63-linked) ubiquitination of IKK-β .

How can UBXN7 antibodies be used in studying virus-host interactions?

UBXN7 antibodies can be powerful tools for investigating virus-host interactions, particularly with HBV:

• Monitoring UBXN7 levels during infection:

  • Track UBXN7 protein levels at different time points post-infection

  • Compare with viral protein expression (HBx for HBV)

  • Assess correlation with viral replication markers

• Analyzing UBXN7-viral protein interactions:

  • Co-immunoprecipitate UBXN7 with viral proteins

  • Map interaction domains using truncation mutants

  • Determine functional consequences of these interactions

• Evaluating post-translational modifications:

  • Monitor UBXN7 ubiquitination during viral infection

  • Identify specific lysine residues targeted for modification

  • Assess how modifications affect UBXN7's antiviral functions

Research has demonstrated that HBV X protein (HBx) interacts with UBXN7 to promote its K48-linked ubiquitination at lysine 99 (K99), leading to UBXN7 degradation. This mechanism allows HBV to counteract UBXN7's inhibitory effect on viral replication .

What methodological approaches are recommended for studying UBXN7's role in autophagy?

UBXN7 has been linked to autophagy regulation, particularly in the context of HBV replication. To investigate this connection:

• Autophagy marker analysis:

  • Monitor LC3 conversion (LC3-I to LC3-II) by Western blot

  • Use GFP-LC3 to visualize autophagosome formation by confocal microscopy

  • Quantify autophagy flux using chloroquine or bafilomycin A1

• Genetic manipulation approaches:

  • Compare wild-type UBXN7 with domain deletion mutants (particularly ΔUAS)

  • Use siRNA-mediated knockdown of UBXN7

  • Create stable cell lines with inducible UBXN7 expression

• Signaling pathway analysis:

  • Monitor NF-κB activity in parallel with autophagy markers

  • Assess IKK-β levels and activation status

  • Use pathway inhibitors to confirm the signaling mechanism

Experimental evidence shows that UBXN7 suppresses HBV-induced autophagy, whereas the UBXN7-ΔUAS mutant (lacking the UAS domain) has no effect. This indicates that the UAS domain is essential for UBXN7's function in regulating autophagy .

How can I optimize immunoprecipitation protocols for detecting UBXN7-binding partners?

Immunoprecipitation (IP) is crucial for studying UBXN7's interactions, but requires optimization:

• Antibody selection and immobilization:

  • Use antibodies validated for IP applications

  • Consider epitope tag systems (Flag-UBXN7) for cleaner results

  • Pre-clear lysates to reduce non-specific binding

• Lysis conditions optimization:

  • Test different lysis buffers (RIPA vs. NP-40 vs. Triton X-100)

  • Include protease and phosphatase inhibitors

  • Add proteasome inhibitors (MG132) to stabilize ubiquitinated complexes

• Analysis of immunoprecipitated complexes:

  • Use sensitive detection methods like MudPIT for comprehensive analysis

  • Perform Western blot validation of key interactions

  • Consider crosslinking approaches for transient interactions

Research has shown that when studying UBXN7's interaction with HIF1α, treatment with MG132 is critical as this interaction is only detectable after proteasome inhibition, which causes accumulation of ubiquitinated HIF1α .

What are emerging areas of research regarding UBXN7 function and antibody applications?

Several promising research directions are emerging in the UBXN7 field:

• Therapeutic targeting:

  • Development of small molecules that modulate UBXN7-HBx interaction

  • Exploring UBXN7 stabilization as an anti-HBV strategy

  • Investigating UBXN7's role in other viral infections

• Systems biology approaches:

  • Proteome-wide analysis of UBXN7 interactors under different conditions

  • Integrating transcriptomics and proteomics data to map UBXN7 regulatory networks

  • Computational modeling of UBXN7's role in protein homeostasis

• Structural biology:

  • Determining crystal structures of UBXN7 domains in complex with binding partners

  • Mapping conformational changes upon substrate binding

  • Structure-based design of modulators of UBXN7 function

Current research suggests that UBXN7 could be targeted for potential new therapies in HBV-related diseases, as it plays a crucial role in inhibiting HBV replication through its effects on NF-κB signaling and autophagy .